Volume 64, Issue 1 pp. 101-110
Original Article
Open Access

Loss of CELF2 promotes skin tumorigenesis and increases drug resistance

Bindeshwar Sah

Bindeshwar Sah

The Hormel Institute, University of Minnesota, Austin, MN, USA

These two authors contributed equally to the article.

Search for more papers by this author
Jasvinder Singh

Jasvinder Singh

The Hormel Institute, University of Minnesota, Austin, MN, USA

These two authors contributed equally to the article.

Search for more papers by this author
Yao Shen

Yao Shen

Department of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA

Search for more papers by this author
Noah Goldfarb

Noah Goldfarb

Department of Internal Medicine and Dermatology, University of Minnesota, Minneapolis, MN, USA

Minneapolis VA Medical Center Health Care System, Minneapolis, Minnesota, USA

Search for more papers by this author
Faramarz H. Samie

Faramarz H. Samie

Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA

Search for more papers by this author
Larisa J. Geskin

Larisa J. Geskin

Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA

Search for more papers by this author
Liang Liu

Corresponding Author

Liang Liu

The Hormel Institute, University of Minnesota, Austin, MN, USA

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

Correspondence

Liang Liu

The Hormel Institute

University of Minnesota

Austin

MN 55912

USA

E-mail: [email protected]

Search for more papers by this author
First published: 17 June 2024
Citations: 1

Conflict of interest: Co-author Noah Goldfarb receives research support from Novartis and DeepX Health for unrelated topics. All other authors declare no conflicts of interest.

Funding source: National Institutes of Health, R01CA196639.

Abstract

Background

CELF2 belongs to the CELF RNA-binding protein family and exhibits antitumor activity in various tumor models. Analysis of the pan-cancer TCGA database reveals that CELF2 expression strongly correlates with favorable prognosis among cancer patients. The function of CELF2 in nonmelanoma skin cancer has not been studied.

Methods

We used shRNA-mediated knockdown (KD) of CELF2 expression in human squamous cell carcinoma (SCC) cells to investigate how CELF2 impacted SCC cell proliferation, survival, and xenograft tumor growth. We determined CELF2 expression in human SCC tissues and adjacent normal skin using immunofluorescence staining. Additionally, we investigated the changes in CELF2 and its target gene expression during UV-induced and chemical-induced skin tumorigenesis by western blotting.

Results

CELF2 KD significantly increased SCC cell proliferation, colony growth, and SCC xenograft tumor growth in immunodeficient mice. CELF2 KD in SCC cells led to activation of KRT80 and GDF15, which can potentially promote cell proliferation and tumor growth. While control SCC cells were sensitive to anticancer drugs such as doxorubicin, SCC cells with CELF2 KD became resistant to drug-induced tumor growth retardation. Finally, we found CELF2 expression diminished during both UV- and chemical-induced skin tumorigenesis in mice, consistent with reduced CELF2 expression in human SCC tumors compared to adjacent normal skin.

Conclusion

This study shows for the first time that CELF2 loss occurs during skin tumorigenesis and increases drug resistance in SCC cells, highlighting the possibility of targeting CELF2-regulated pathways in skin cancer prevention and therapies.

Data availability statement

The data generated during the current study are available from the corresponding author upon reasonable request. RNA-seq datasets were deposited into the Gene Expression Omnibus (GEO) database repository (GSE244862).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.